公开(公告)号：US20120295349A1

公开(公告)日：2012-11-22

申请号：US13555495

申请日：2012-07-23

申请人： TSUI-JUNG CHANG ,  Chih-Hsien Chang ,  Ya-Jen Chang ,  Te-Wei Lee ,  Tin-Yun Ho ,  Chien-yun Hsiang

发明人： TSUI-JUNG CHANG ,  Chih-Hsien Chang ,  Ya-Jen Chang ,  Te-Wei Lee ,  Tin-Yun Ho ,  Chien-yun Hsiang

IPC分类号： C12N5/10

CPC分类号： G01N33/5008

摘要： A mammal dedicated cell line is provided, which is a HepG2 hepatocellular carcinoma cell line (HepG2/NF-kB/Luc/sr39tk)1_18 obtained by co-transformation with NF-kB/Luc and NF-kB/sr39tk. Firstly, a successfully transformed pNF-kB/Luc HepG2 cell is obtained. Then, a dedicated cell line sensitive to TPA and MTX is generated by experimental screening Next, a plasmid construct carrying pNF-kB/sr39tk genome is introduced into the dedicated cell line by means of Superfect protocol. Finally, a HepG2 cell line co-expressing NF-kB/Luc and NF-kB/sr39tk is screened with G418 and ZEOCIN, and transformation result is confirmed by luminescence and radio activity. The (HepG2/NF-kB/Luc/sr39tk)1_18 obtained is suitable to screen drug for treating liver cancer and examine these cells by bioluminescence imaging and nuclear medicine imaging.

摘要翻译： 提供哺乳动物专用细胞系，其是通过与NF-kB / Luc和NF-kB / sr39tk共转化获得的HepG2肝细胞癌细胞系（HepG2 / NF-kB / Luc / sr39tk）1-18。 首先，获得成功转化的pNF-kB / Luc HepG2细胞。 然后，通过实验筛选产生对TPA和MTX敏感的专用细胞系。接下来，通过Superfect方案将携带pNF-kB / sr39tk基因组的质粒构建体导入专用细胞系。 最后，用G418和ZEOCIN筛选共表达NF-kB / Luc和NF-kB / sr39tk的HepG2细胞株，通过发光和放射活性证实转化结果。 获得的（HepG2 / NF-kB / Luc / sr39tk）1_18适用于筛选药物治疗肝癌，并通过生物发光成像和核医学成像检查这些细胞。

公开(公告)号：US20100216232A1

公开(公告)日：2010-08-26

申请号：US12506572

申请日：2009-07-21

申请人： TSUI-JUNG CHANG ,  CHIH-HSIEN CHANG ,  YA-JEN CHANG ,  TE-WEI LEE ,  TIN-YUN HO ,  CHIEN-YUN HSIANG

发明人： TSUI-JUNG CHANG ,  CHIH-HSIEN CHANG ,  YA-JEN CHANG ,  TE-WEI LEE ,  TIN-YUN HO ,  CHIEN-YUN HSIANG

IPC分类号： C12N5/10 ,  C12N5/071

CPC分类号： G01N33/5008

摘要： A mammal dedicated cell line is provided, which is a HepG2 hepatocellular carcinoma cell line (HepG2/NF-kB/Luc/sr39tk)1_18 obtained by co-transformation with NF-kB/Luc and NF-kB/sr39tk. Firstly, a successfully transformed pNF-kB/Luc HepG2 cell is obtained. Then, a dedicated cell line sensitive to TPA and MTX is generated by experimental screening Next, a plasmid construct carrying pNF-kB/sr39tk genome is introduced into the dedicated cell line by means of Superfect protocol. Finally, a HepG2 cell line co-expressing NF-kB/Luc and NF-kB/sr39tk is screened with G418 and ZEOCIN, and transformation result is confirmed by luminescence and radio activity. The (HepG2/NF-kB/Luc/sr39tk)1_18 obtained is suitable to screen drug for treating liver cancer and examine these cells by bioluminescence imaging and nuclear medicine imaging.

摘要翻译： 提供哺乳动物专用细胞系，其是通过与NF-kB / Luc和NF-kB / sr39tk共转化获得的HepG2肝细胞癌细胞系（HepG2 / NF-kB / Luc / sr39tk）1-18。 首先，获得成功转化的pNF-kB / Luc HepG2细胞。 然后，通过实验筛选产生对TPA和MTX敏感的专用细胞系。接下来，通过Superfect方案将携带pNF-kB / sr39tk基因组的质粒构建体导入专用细胞系。 最后，用G418和ZEOCIN筛选共表达NF-kB / Luc和NF-kB / sr39tk的HepG2细胞株，通过发光和放射活性证实转化结果。 获得的（HepG2 / NF-kB / Luc / sr39tk）1_18适用于筛选药物治疗肝癌，并通过生物发光成像和核医学成像检查这些细胞。

公开(公告)号：US20110097263A1

公开(公告)日：2011-04-28

申请号：US12606529

申请日：2009-10-27

申请人： WEI-CHUAN HSU ,  TE-WEI LEE ,  CHIA-YU YU ,  CHIH-HSIEN CHANG ,  TSUI-JUNG CHANG

发明人： WEI-CHUAN HSU ,  TE-WEI LEE ,  CHIA-YU YU ,  CHIH-HSIEN CHANG ,  TSUI-JUNG CHANG

IPC分类号： A61K51/04 ,  A61K51/00

CPC分类号： A61K51/1234 ,  A61K47/6913

摘要： A kit formulation for the preparation of immunoliposome drug in combined chemotherapy and radionuclide therapy is disclosed, which consists: (1) a vial A containing proteins; (2) a vial B containing Traut's reagent; (3) a vial C containing DSPC, Cholesterol, mPEG-DSPE, Mal-DSPE-PEG and chemotherapy drug; (4) a vial D containing BMEDA, gluconate acetate, SnCl2; (5) a vial E which containing radionuclide solution. The procedure using the kit comprises: (i) withdraw the radionuclide solution from the vial E; (ii) inject the solution into the vial D for enabling reaction; (iii) withdraw the contents of the vial B and inject into the vial A; (iv) withdraw the contents of the protein and Traut's reagent mixtures from the vial A and inject into the vial C for enabling reaction; (v) withdraw the contents of the immunoliposome from the vial C; (vi) inject the immunoliposome into the vial D of step (ii) for enabling reaction.

摘要翻译： 公开了用于在联合化疗和放射性核素治疗中制备免疫脂质体药物的试剂盒制剂，其包括：（1）含有蛋白质的小瓶A; （2）含有Traut试剂的小瓶B; （3）含有DSPC，胆固醇，mPEG-DSPE，Mal-DSPE-PEG和化疗药物的小瓶C; （4）含有BMEDA，葡萄糖酸乙酯，SnCl 2的小瓶D; （5）含有放射性核素溶液的小瓶E. 使用试剂盒的方法包括：（i）从小瓶E中取出放射性核素溶液; （ii）将溶液注入小瓶D以进行反应; （iii）取出小瓶B的内容物并注入小瓶A; （iv）从小瓶A取出蛋白质和Traut试剂混合物的内容物，并注入小瓶C以进行反应; （v）从小瓶C取出免疫脂质体的内容物; （vi）将免疫脂质体注射到步骤（ii）的小瓶D中以进行反应。